



**Preliminary Final Report of
Vita Life Sciences Limited
For the Year Ended 31 December 2015**

This Preliminary Final Report is provided to the Australian Securities Exchange (“ASX”) under ASX Listing Rule 4.3A

Current Reporting Period:

Financial Year Ended 31 December 2015

Previous Corresponding Period:

Financial Year Ended 31 December 2014

**Vita Life Sciences Limited and its Controlled Entities
ABN 35 003 190 421**

Contents

Results for announcement to the market	3
Commentary on Results	4
Consolidated Statement of Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Cash Flows	8
Consolidated Statement of Changes in Equity	9
Notes to the Financial Statements	11
Compliance Statement	42

Name of Entity: Vita Life Sciences Limited

ABN: 35 003 190 421

Results for announcement to the market

		Percentage Change %	2015 A\$'000
Revenue	up	5.48%	38,584
Profit from continuing operations before tax and finance	down	-11.44%	6,095
Profit before income tax	down	-13.33%	6,002
Net profit after tax	down	-40.27%	4,351
Net profit attributable to members	down	-39.68%	4,391

Dividends (distributions)		Franked amount per security	Conduit Foreign Income
Interim dividend per share	1.5 cents	0.0 cents	1.5 cents
Final dividend per share	2.25 cents	0.0 cents	<i>Amount to be determined</i>

Record date for determining entitlements to dividends

18/03/2016

Payment date

24/03/2016

The Company's dividend reinvestment plan remains suspended, and as such does not apply to the final dividend.

Commentary on Results

Brief explanation of any of the figures above necessary to enable the figures to be understood

Directors are pleased with the financial results of Vita Life Sciences Limited and its subsidiaries (the Group), particularly given the slow start to the year.

For the Group it was a tale of 2 half's, both in terms of revenue and EBIT. After a solid sales result in the 1st half, sales of our products increased in the 2nd half reaching \$38.6m for the full year. EBIT rebounded strongly in the 2nd half to \$3.7m; an increase of 54.2% over the \$2.4m recorded in the 1st half, however was not enough to offset the 1st half, with Group EBIT of \$6.1m being down 11.6% on 2014.

Pleasingly the Group continued to generate substantial gross operating cash, \$5.7m; a direct result of strict financial management and discipline.

On the basis of the healthy profit and cash generation, Directors have increased the final dividend to 2.25 cents per share (unfranked) for the 2015 financial year; a total of 3.75 cents per share for the 2015 financial year (2014: 3.5 cents per share).

Other key financial results were:

- 8th consecutive year of sales growth since listing on the ASX in 2007
- The Australian business was the Groups standout performer achieving record sales resulting in EBIT increasing to \$3.1m, an increase of 18.8% over 2014.
- Strong cash flow continues to be a strength of the business, with gross operating cashflow of 92% of EBITDA.
- Continued prudent financial management, with the Company maintaining a net cash balance sheet, while:
 - Returning \$2.6m to shareholders through dividend payments and the share buyback; and
 - Reducing borrowings associated with the Malaysian central facility to \$2.8m and additional capital investment of \$0.6m in that facility.

Divisional Results

The Group's divisional result for the financial year is summarised in the table below.

	Health \$'000	Investment \$'000	Total \$'000
Result			
Segment profit / (loss) before interest and tax	6,754	(21)	6,733
Unallocated expenses			(638)
Profit before interest and tax			6,095
Finance costs			(93)
Profit before income tax			6,002
Income tax expense			(1,651)
Net profit for the year			4,351

Australia

The financial results from Australian operations were excellent. Revenue increased by 13.8% to \$15.6m which had a favourable impact on EBIT of \$3.1m, up 18.8% on 2014.

The build-out of the pharmacy brand 'Vita Sciences' through independent pharmacies in Australia continued successfully in 2015. International distribution arrangements for Herbs of Gold brand products was secured during the year and sales expectations have been in line with those expectations.

Commentary on Results (continued)

Divisional Results (continued)

The strategy for Australia is unchanged: to maintain our point of differentiation in the Australian healthcare OTC market by continuing to exclusively distribute unique premium ingredient product formulations through independent retailers. Management believes this policy positions the Group for long term growth and sustainability in a mature and competitive market.

Malaysia

After a slow start to the year, the performance of the Malaysian OTC business was pleasing, particularly in the second half of 2015. Strong sales momentum in the 2nd half of 'Vita Health', considered one of Malaysia's leading OTC health supplement brands, resulted in sales increasing 4.4% to \$14.4m and EBIT of \$1.9m, down on 2014's \$2.6m.

Overall directors view the Malaysian result as satisfactory given the difficult economic and trading conditions in that country in 2015.

Singapore

A reinvigorated sales and marketing effort in Singapore led to sales of \$6.3m, up 10.6% on 2014. EBIT of \$2.1m was similar to that achieved in 2014 due to strong competition.

Other Asia

Revenue in the Group's expanding markets, namely China, Malaysia – Multi Level Marketing, Thailand, Vietnam and Indonesia, contracted to \$2.3m in 2015, or by 32.3% when compared to 2014. The contraction in sales resulted from the planned introduction of a new management team in Thailand and the inability to obtain registration of products in China under its new regulatory regime. The bright light in our expansion markets was Vietnam, which continued on its previously established growth path.

Indonesian operations commenced late in 2015 with initial sales from early 2016.

Strategic Initiatives in 2016

The Board's planned expansion of the Group's senior management team with the appointment of 2 CEO's: Mr. Andrew O'Keefe in Australia and Mr. Danny Tan in Malaysia and Singapore has been completed. With these key executives in place the Group's Managing Director will focus on bringing our other Asian markets to critical mass.

Strategies to capitalise on the established Australian Asia-Pacific platform continue to be explored. Two key mature market growth initiatives which will continue during 2016 are:

- Build out of the pharmacy brand 'Vita Sciences' through independent pharmacies in Australia
- Build out our Australian health brand 'Herbs of Gold' in the Singaporean and Malaysian markets.

Outlook for 2016

Directors foreshadow the steady growth of recent years to continue in 2016. Given the Company's diverse operating platform the Directors intend to provide more detailed guidance mid-way through the year.

Consolidated Statement of Comprehensive Income

for the year ended 31 December 2015	Notes	2015 \$'000	2014 \$'000
CONTINUING OPERATIONS			
Sale of goods		38,584	36,580
Cost of sales		(11,430)	(10,538)
Gross profit		27,154	26,042
Other income	3 (a)	37	171
Distribution expenses		(3,470)	(2,982)
Marketing expenses		(2,960)	(2,639)
Occupancy expenses		(893)	(845)
Administrative expenses	3 (b)	(13,506)	(12,650)
Other expenses	3 (c)	(254)	(212)
Share of associate's loss		(13)	(3)
Profit from continuing operations before interest and taxes		6,095	6,882
Finance income	3 (d)	161	174
Finance costs	3 (e)	(254)	(131)
Profit before income tax		6,002	6,925
Income tax benefit / (expense)	5	(1,651)	359
Net profit for the year		4,351	7,284
Other comprehensive income after income tax			
Items that will be reclassified subsequently to profit or loss when specific conditions are met:			
Exchange differences on translating foreign controlled entities		(690)	415
Other comprehensive income (loss) for the year, net of income tax		(690)	415
Total comprehensive income for the year		3,661	7,699
Net profit/(loss) for the year attributable to:			
Non-controlling interest		(40)	4
Members of the parent		4,391	7,280
		4,351	7,284
Total comprehensive income attributable to:			
Non-controlling interest		(6)	2
Members of the parent		3,667	7,697
		3,661	7,699
Earnings per share (cents per share)			
- basic earnings per share	4	7.89	12.98
- diluted earnings per share	4	7.69	12.84

The accompanying notes should be read in conjunction with the above Statement of Comprehensive Income

Consolidated Statement of Financial Position

as at 31 December 2015	Notes	2015 \$'000	2014 \$'000
ASSETS			
Current Assets			
Cash and cash equivalents	6	9,734	9,158
Trade and other receivables	7	6,482	6,041
Inventories	8	6,593	5,012
Other assets	9	715	598
Total Current Assets		23,524	20,809
Non Current Assets			
Other assets	9	5	-
Investment in associates	10	937	1,044
Property, plant and equipment	11	7,629	6,910
Intangible assets	12	86	97
Deferred tax assets	5 (c)	207	1,411
Total Non Current Assets		8,864	9,462
Total Assets		32,388	30,271
LIABILITIES			
Current Liabilities			
Trade and other payables	13	5,785	4,312
Interest bearing loans and borrowings	14	243	260
Current tax liability	5 (c)	178	439
Provisions	15	663	523
Total Current Liabilities		6,869	5,534
Non Current Liabilities			
Deferred Tax Liability	5 (c)	21	9
Interest bearing loans and borrowings	14	2,567	3,094
Provisions	15	55	69
Total Non Current Liabilities		2,643	3,172
Total Liabilities		9,512	8,706
Net Assets		22,876	21,565
EQUITY			
Contributed equity	16	44,911	45,429
Accumulated losses		(21,863)	(24,307)
Employee share based payments reserve		958	704
Foreign currency translation reserve		(1,180)	(357)
Parent entity interest		22,826	21,469
Non-controlling interest		50	96
Total Equity		22,876	21,565

The accompanying notes should be read in conjunction with the above Statement of Financial Position

Consolidated Statement of Cash Flows

For the year ended 31 December 2015	Notes	2015 \$'000	2014 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		42,341	38,971
Payments to suppliers and employees		(36,579)	(31,951)
Income tax paid		(835)	(1,019)
Interest received		161	174
Borrowing costs		(165)	(60)
Net cash flows provided by operating activities	6	4,923	6,115
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from sale of property, plant and equipment		20	-
Purchase of property, plant and equipment		(879)	(6,778)
Net cash flows used in investing activities		(859)	(6,778)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from external borrowings		2,811	3,375
Repayment of external borrowings		(3,355)	(21)
Proceeds from issue of shares		88	-
Dividends Paid		(1,947)	(1,964)
Shares bought back (net of costs)		(606)	(671)
Net cash flows provided by / (used in) financing activities		(3,009)	719
Net increase in cash and cash equivalents		1,055	56
Net foreign exchange differences		(479)	129
Cash and cash equivalents at beginning of the year		9,158	8,973
Cash and cash equivalents at end of the year	6	9,734	9,158

The accompanying notes should be read in conjunction with the above Statement of Cash Flows

Consolidated Statement of Changes in Equity

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2015		45,429	704	(24,307)	(357)	21,469	96	21,565
Comprehensive income								
Profit attributable to members of parent entity		-	-	4,391	-	4,391	(40)	4,351
Other comprehensive income (loss) for the year		-	-	-	(823)	(823)	(6)	(829)
Total comprehensive income for the year		-	-	4,391	(823)	3,568	(46)	3,522
Transactions with owners, in their capacity as owners								
Shares bought back		(606)	-	-	-	(606)	-	(606)
Repayment of loans on Employee share option scheme		88	-	-	-	88	-	88
Employee share option scheme		-	254	-	-	254	-	254
Dividends paid	16(d)	-	-	(1,947)	-	(1,947)	-	(1,947)
Total transactions with owners		(518)	254	(1,947)	-	(2,211)	-	(2,211)
Balance at 31 December 2015		44,911	958	(21,863)	(1,180)	22,826	50	22,876

The accompanying notes should be read in conjunction with the above Statement of Changes in Equity

Consolidated Statement of Changes in Equity (continued)

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2014		46,100	472	(29,623)	(770)	16,179	90	16,269
Comprehensive income								
Profit attributable to members of parent entity		-	-	7,280	-	7,280	4	7,284
Other comprehensive income for the year		-	-	-	413	413	2	415
Total comprehensive income for the year		-	-	7,280	413	7,693	6	7,699
Transactions with owners, in their capacity as owners								
Shares bought back		(671)	-	-	-	(671)	-	(671)
Employee share option scheme		-	232	-	-	232	-	232
Dividends paid		-	-	(1,964)	-	(1,964)	-	(1,964)
Total transactions with owners		(671)	232	(1,964)	-	(2,403)	-	(2,403)
Balance at 31 December 2014		45,429	704	(24,307)	(357)	21,469	96	21,565

The accompanying notes should be read in conjunction with the above Statement of Changes in Equity

Notes to the Financial Statements

For the Year Ended 31 December 2015

1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of preparation

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board (AASB) and the *Corporations Act 2001*. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

Except for cash flow information, the financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

(b) Statement of compliance

The financial report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standards ("AIFRS"). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards ("IFRS").

(c) Basis of consolidation

The consolidated financial statements comprise the financial statements of Vita Life Sciences Limited and its subsidiaries ("the Group") as at 31 December 2015. Interests in associates are equity accounted and are not part of the consolidated Group.

Subsidiaries are all those entities over which the Group has the power to govern the financial and operating policies so as to obtain benefits from their activities. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether a group controls another entity.

The financial statements of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.

In preparing the consolidated financial statements, all intercompany balances and transactions, income and expenses and profit and losses resulting from intra-group transactions have been eliminated in full.

Subsidiaries are fully consolidated from the date on which control is obtained by the Group and cease to be consolidated from the date on which control is transferred out of the Group.

Investments in subsidiaries held by Vita Life Sciences Limited are accounted for at cost in the separate financial statements of the parent entity.

The acquisition of subsidiaries is accounted for using the purchase method of accounting. The purchase method of accounting involves allocating the cost of the business combination to the fair value of the assets acquired and the liabilities and contingent liabilities assumed at the date of acquisition.

Minority interests represent the interests in Vita Life Sciences (Thailand) Co. Ltd and Vitahealth (Thailand) Co. Ltd not held by the Group. Minority interests are allocated their share of net profit or loss after tax in the statement of comprehensive income and are presented within Equity in the consolidated statement of financial position, separately from the parent shareholders' equity.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(d) Business combinations

The purchase method of accounting is used to account for all business combinations regardless of whether equity instruments or other assets are acquired. Cost is measured as the fair value of the assets given, shares issued or liabilities incurred or assumed at the date of exchange plus cost directly attributable to the combination. Where equity instruments are issued in a business combination, the fair value of the instruments is their published market price as at the date of exchange. Transaction costs arising from the issue of equity instruments are recognised directly in equity.

Except for non-current assets classified as held for sale (which are measured at fair value less costs to sell), all identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The excess of the cost of the business combination over the net fair value of the Group's share of the identifiable net assets acquired is recognised as goodwill. If the cost of acquisition is less than the Group's share of the net fair value of the identifiable net assets of the subsidiary, the difference is recognised as a gain in the statement of comprehensive income, but only after a reassessment of the identification and measurement of the net assets acquired.

Where settlement of any part of the consideration is deferred, the amounts payable in the future are discounted to their present values as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions.

(e) Foreign currency translation

(i) Functional and presentation currency

Both the functional and presentation currency of Vita Life and its Australian subsidiaries are Australian dollars (\$).

The functional currency of the main operating overseas subsidiaries Vita Healthcare Asia Pacific Sdn Bhd, Swiss Bio Pharma Sdn Bhd, Vitaron Jaya Sdn Bhd, Vita Life Sciences Sdn Bhd and Pharma Direct Sdn Bhd are in Malaysian Ringgit (MYR), whilst Vitahealth IP Pte Ltd, VitaHealth Asia Pacific (S) Pte Ltd, Supplements World Pte Ltd and Vita Corporation Pte Limited are in Singapore dollars (SGD).

(ii) Transactional and balances

Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

The exchange differences arising on the retranslation are taken directly to a separate component of equity.

On disposal of a foreign entity, the deferred cumulative amount recognised in equity relating to that particular foreign operation is recognised in the statement of comprehensive income.

(f) Cash and cash equivalents

Cash and cash equivalents in the statement of financial position comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(g) Trade and other receivables

Trade receivables, which generally have 30-90 day terms, are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment.

Collectability of trade receivables is reviewed on an ongoing basis at an operating unit level. Individual debts that are known to be uncollectible are written off when identified. An impairment provision is recognised when there is objective evidence that the Group will not be able to collect the receivable. Financial difficulties of the debtor or default payments are considered objective evidence of impairment. The amount of the impairment loss is the receivable carrying amount compared to the present value of estimated future cash flows, discounted at the original effective interest rate.

(h) Inventory

Inventories including raw materials are valued at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated selling costs.

Costs incurred in bringing each product to its present location and condition is accounted for as follows:

Raw materials – purchase cost on a first-in, first-out basis.

Finished goods and work-in-progress – cost of direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity but excluding borrowing costs.

(i) Property, plant and equipment

Plant and equipment is measured at cost less accumulated depreciation and impairment losses.

The cost of fixed assets constructed within the economic entity includes the cost of materials, direct labour, borrowing costs and an appropriate proportion of fixed and variable overheads. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be reliably. All other repairs and maintenance are charged to the statement of comprehensive income during the financial period in which they are incurred.

Depreciation

The depreciable amounts of all fixed assets including capitalised lease assets are depreciated on a straight-line basis over the estimated useful lives. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows:

	<u>Rate</u>	<u>Method</u>
Buildings	2%	Straight-line method
Plant and equipment	10-33%	Straight-line method
Leasehold Improvements	20-50%	Straight-line method
Motor Vehicles	20-50%	Straight-line method

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the statement of comprehensive income in the year the item is derecognised.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(j) Goodwill and Intangibles

Goodwill

Goodwill acquired in a business combination is initially measured at cost being the excess of the cost of the business combination over the Group's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities.

From the initial recognition, goodwill is measured at cost less any accumulated impairment losses.

For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or group of units.

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units), to which the goodwill relates.

When the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. When goodwill forms part of a cash-generating unit (group of cash-generating units) and an operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this manner is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained. Impairment losses recognised for goodwill are not subsequently reversed.

Intangibles

Intangible assets acquired separately are capitalised at cost and from a business combination are capitalised at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the year in which the expenditure is incurred.

The useful lives of these intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over the useful life and tested for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the assets are accounted for prospectively by changing the amortisation period or method, as appropriate, which is a change in accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in profit or loss in the expense category consistent with the function of the intangible asset.

Intangible assets with indefinite useful lives are tested for impairment annually either individually or at that cash-generating unit level consistent with the methodology outlined for goodwill above. Such intangibles are not amortised. The useful life of an intangible asset with an indefinite life is reviewed each reporting period to determine whether indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for as a change in an accounting estimate and is thus accounted for on prospective basis.

A summary of the policies applied to the Group's intangible asset is as follows:

	<u>Patents and licences</u>	<u>Development costs</u>
Useful lives	Indefinite	Finite
Method used	Not depreciated or revalued	3 years – Straight line
Internally generated/ Acquired	Acquired	Internally generated
Impairment test / Recoverable amount testing	Annually and where an indicator of impairment exists	Amortisation method reviewed at each financial year-end annually for indicator of impairment

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(k) Impairment of non-financial assets other than goodwill

Intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicated that the carrying amount may not be recoverable.

An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash inflows are largely independent of the cash inflows from other assets or group of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are tested for possible reversal of the impairment whenever events or changes in circumstances indicate that the impairment may have reversed.

(l) Trade and other payables

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. Trade payables are normally settled within 30 to 90 days.

(m) Interest bearing loans and borrowings

All loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of issue costs associated with the borrowing.

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest method. Amortised cost is calculated by taking into account any issue costs and any discount or premium on settlement.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Borrowing costs

Borrowing costs are recognised as an expense when incurred. Borrowing costs that are directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to prepare for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

(n) Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

(o) Employee entitlements

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

Employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled plus related on-costs. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. In determining the present value of future cash outflows, the market yield as at the reporting date on national government bonds, which have terms to maturity approximating the terms of the related liability, are used.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(o) Employee entitlements (continued)

Employee benefit expenses and revenues arising in respect of wages and salaries, non-monetary benefits, annual leave, long service leave and other leave benefits; and other types of employee benefits are recognised against profits on a net basis in their respective categories.

(p) Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the gross proceeds.

(q) Leases

Finance Leases

Leases of fixed assets, which substantially transfer to the Group all risks and benefits incidental to ownership of the leased item, but not the legal ownership, are classified as finance leases. Finance leases are capitalised at the inception of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Leased assets are depreciated over the shorter of the estimated useful life of the asset or the lease term. Lease payments are apportioned between the finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly against income.

Operating Leases

Leases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases. Operating lease payments are recognised as an expense in the statement of comprehensive income on a straight-line basis over the lease term. Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease.

(r) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

Revenue is recognised (net of returns, discounts and allowances excluding distributors cost) when the significant risks and rewards of ownership of the goods have passed to the buyer and can be measured reliably.

Consequently, transfers of goods to major distributors are considered as consignment inventory and revenue is only recognised upon the achievement of "in-market" sales.

Interest

Revenue is recognised as the interest accrues (using the effective interest rate method, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument) to the net carrying amount of the financial asset.

Dividends

Revenue is recognised when the Group's right to receive the payment is established.

(s) Taxes

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the current period's taxable income. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at balance sheet date.

Deferred income tax is provided on all temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amounts for financial reporting purposes.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(s) Taxes (continued)

Deferred income tax liabilities are recognised for all taxable temporary differences:

- except where the deferred income tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, except where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax assets and unused tax losses can be utilised:

- except where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred income tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Unrecognised deferred income tax assets are reassessed at each balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

Tax consolidation

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was 30 June 2003.

Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "stand-alone basis without adjusting for intercompany transactions" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts payable (receivable) to (from) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised.

Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

(t) Other taxes

Revenues, expenses and assets are recognised net of the amount of Goods and Services Tax ("GST") except:

- where the GST incurred is not recoverable from the Australian Taxation Office ("ATO"), and is therefore recognised as part of the asset's cost or as part of the expense item.
- Receivables and payables are stated inclusive of GST.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(t) Other taxes (continued)

The net amount of GST recoverable from, or payable to, the ATO is included as part of receivables or payables in the statement of financial position. Cash flows are presented in the Statement of Cash Flow on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to the taxation authority are classified as operating cash flows.

(u) Financial instruments

Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out below.

Financial assets at fair value through profit and loss

A financial asset is classified in this category if acquired principally for the purpose of selling in the short term, or if so designated by management and within the requirement of AASB139: Recognition and Measurement of Financial Instruments.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

De-recognition of financial instruments

Financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- the rights to receive cash flows from the asset have expired;
- the Group retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a 'pass-through' arrangement; or
- the Group has transferred its rights to receive cash flows from the asset and either (a) has transferred substantially all the risks and rewards of the asset, or (b) has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Group's continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration received that the Group could be required to repay.

Financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed. Any subsequent reversal of an impairment loss is recognised in profit or loss, to the extent that the carrying value of the asset does not exceed its amortised cost at the reversal date.

Financial assets carried at amortised cost

If there is objective evidence that an impairment loss on loans and receivables carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The carrying amount of the asset is reduced either directly or through use of an allowance account. The amount of the loss is recognised in profit or loss.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(u) Financial instruments (continued)

The Group first assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, and individually or collectively for financial assets that are not individually significant. If it is determined that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, the asset is included in a group of financial assets with similar credit risk characteristics and that group of financial assets is collectively assessed for impairment. Assets that are individually assessed for impairment and for which an impairment loss is or continues to be recognised are not included in a collective assessment of impairment.

Financial assets carried at cost

If there is objective evidence that an impairment loss has been incurred on an unquoted equity instrument that is not carried at fair value (because its fair value cannot be reliably measured), or on a derivative asset that is linked to and must be settled by delivery of such an unquoted equity instrument, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the current market rate of return for a similar financial asset.

(v) Earnings per share

Basic earnings per share

Basic earnings per share is determined by dividing the net profit/(loss) after income tax attributable to members of the Company by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.

Diluted earnings per share

Diluted earnings per share adjust the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

(w) Share-based payment transactions

(i) Equity settled transactions:

The Group provides benefits to its employees (including key management personnel) in the form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).

The cost of the equity-settled transactions with employees is measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using the Black-Scholes model. In valuing equity-settled transactions, no account is taken of any vesting conditions, other than conditions linked to the price of the shares of Vita Life Sciences Limited (market conditions) if applicable.

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date).

At each subsequent reporting date until vesting, the cumulative charge to the statement of comprehensive income is the product of:

- (i) the grant date fair value of the award;
- (ii) the current best estimate of the number of awards that will vest, taking into account such factors as the likelihood of employee turnover during the vesting period and the likelihood of non-market performance conditions being met; and
- (iii) the expired portion of the vesting period.

The charge to the statement of comprehensive income for the period is the cumulative amount as calculated above less the amounts already charged in previous periods. There is a corresponding entry to equity.

Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards are vested than were originally anticipated to do so. Any award subject to a market condition is considered to vest irrespective of whether or not that market condition is fulfilled, provided that all other conditions are satisfied.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(w) Share-based payment transactions (continued)

If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. An additional expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.

If an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled and new award are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(x) New Accounting Standards and Interpretations for Application in Future Periods

Accounting Standards and Interpretations issued by the AASB that are not yet mandatorily applicable to the Group, together with an assessment of the potential impact of such pronouncements on the Group when adopted in future periods, are discussed below:

AASB 2014-1: Amendments to Australian Accounting Standards (Part D)

Part D of this Standard is applicable to annual reporting periods beginning on or after 1 January 2016 and makes amendments to AASB 1: First-time Adoption of Australian Accounting Standards, which arise from the issuance of AASB 14: Regulatory Deferral Accounts in June 2014. AASB 14 permits first-time adopters to continue to account for amounts related to rate regulation in accordance with their previous GAAP when they adopt Australian Accounting Standards. In line with management's assessment of AASB 14, this part is not expected to have a significant impact on the Group's financial statements.

AASB 9: Financial Instruments and associated Amending Standards (applicable to annual reporting periods beginning on or after 1 January 2018)

The Standard will be applicable retrospectively (subject to the provisions on hedge accounting outlined below) and includes revised requirements for the classification and measurement of financial instruments, revised recognition and derecognition requirements for financial instruments and simplified requirements for hedge accounting.

The key changes made to the Standard that may affect the Group on initial application include certain simplifications to the classification of financial assets, simplifications to the accounting of embedded derivatives, and the irrevocable election to recognise gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. AASB 9 also introduces a new model for hedge accounting that will allow greater flexibility in the ability to hedge risk, particularly with respect to hedges of non-financial items. Should the entity elect to change its hedge policies in line with the new hedge accounting requirements of AASB 9, the application of such accounting would be largely prospective.

Although the directors anticipate that the adoption of AASB 9 may have an impact on the Group's financial instruments, including hedging activity, it is impracticable at this stage to provide a reasonable estimate of such impact.

AASB 15: Revenue from Contracts with Customers (applicable to annual reporting periods beginning on or after 1 January 2018)

When effective, this Standard will replace the current accounting requirements applicable to revenue with a single, principles-based model. Except for a limited number of exceptions, including leases, the new revenue model in AASB 15 will apply to all contracts with customers as well as non-monetary exchanges between entities in the same line of business to facilitate sales to customers and potential customers. The core principle of the Standard is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the goods or services. To achieve this objective, AASB 15 provides the following five-step process:

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(x) New Accounting Standards and Interpretations for Application in Future Periods (continued)

- identify the contract(s) with a customer;
- identify the performance obligations in the contract(s);
- determine the transaction price;
- allocate the transaction price to the performance obligations in the contract(s); and
- recognise revenue when (or as) the performance obligations are satisfied.

The transitional provisions of this Standard permit an entity to either: restate the contracts that existed in each prior period presented as per AASB 108: Accounting Policies, Changes in Accounting Estimates and Errors (subject to certain practical expedients in AASB 15); or recognise the cumulative effect of retrospective application to incomplete contracts on the date of initial application. There are also enhanced disclosure requirements regarding revenue.

Although the directors anticipate that the adoption of AASB 15 may have an impact on the Group's financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.

AASB 2014-3: Amendments to Australian Accounting Standards – Accounting for Acquisitions of Interests in Joint Operations (applicable to annual reporting periods beginning on or after 1 January 2016)

This Standard amends AASB 11: Joint Arrangements to require the acquirer of an interest (both initial and additional) in a joint operation in which the activity constitutes a business, as defined in AASB 3: Business Combinations, to apply all of the principles on business combinations accounting in AASB 3 and other Australian Accounting Standards except for those principles that conflict with the guidance in AASB 11; and disclose the information required by AASB 3 and other Australian Accounting Standards for business combinations.

The application of AASB 2014-3 will result in a change in accounting policies for the above described transactions, which were previously accounted for as acquisitions of assets rather than applying the acquisition method as per AASB 3. The transitional provisions require that the Standard should be applied prospectively to acquisitions of interests in joint operations occurring on or after 1 January 2016. As at 31 December 2015, management is not aware of the existence of any such arrangements that would impact the financial statements of the entity going forward and as such is not capable of providing a reasonable estimate at this stage of the impact on initial application of the Standard.

AASB 2014-10: Amendments to Australian Accounting Standards – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (applicable to annual reporting periods beginning on or after 1 January 2016)

This Standard amends AASB 10: Consolidated Financial Statements with regards to a parent losing control over a subsidiary that is not a "business" as defined in AASB 3 to an associate or joint venture, and requires that:

- a gain or loss (including any amounts in other comprehensive income (OCI)) be recognised only to the extent of the unrelated investor's interest in that associate or joint venture;
- the remaining gain or loss be eliminated against the carrying amount of the investment in that associate or joint venture; and
- any gain or loss from remeasuring the remaining investment in the former subsidiary at fair value also be recognised only to the extent of the unrelated investor's interest in the associate or joint venture. The remaining gain or loss should be eliminated against the carrying amount of the remaining investment.

The application of AASB 2014-10 will result in a change in accounting policies for transactions of loss of control over subsidiaries (involving an associate or joint venture) that are businesses as per AASB 3 for which gains or losses were hitherto recognised only to the extent of the unrelated investor's interest.

The transitional provisions require that the Standard should be applied prospectively to sales or contributions of subsidiaries to associates or joint ventures occurring on or after 1 January 2016. As at 31 December 2015, management is not aware of the existence of any such arrangements that would impact the financial statements of the entity going forward and as such is not capable of providing a reasonable estimate at this stage of the impact on initial application of the standard.

(y) New and Amended Accounting Policies Adopted by the Group

The Group adopted the following Australian Accounting Standards from the mandatory application date of 1 January 2015:

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

1 Summary of Significant Accounting Policies (continued)

(y) New and Amended Accounting Policies Adopted by the Group (continued)

AASB 2014-1: Amendments to Australian Accounting Standards (Part E)

Part E of this Standard is applicable to annual reporting periods beginning on or after 1 January 2015 and defers the application date of AASB 9 (December 2010) to annual reporting periods beginning on or after 1 January 2018. This part also makes consequential amendments to hedge accounting disclosures set out in AASB 7: Financial Instruments: Disclosures, and to AASB 132: Financial Instruments: Presentation to permit irrevocable designation of "own use contracts" as measured at fair value through profit or loss if the designation eliminates or significantly reduces an accounting mismatch. Management believes that there will not be any significant impact on the Group's financial statements on adoption of this part of the Standard.

(z) Significant accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates on historical experience and on other various factors it believes to be reasonable under the circumstances, the result of which form the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

Management has identified the following critical accounting policies for which significant judgements, estimates and assumptions are made. Actual results may differ from these estimates under different assumptions and conditions and may materially affect financial results or the financial position reported in future periods.

Further details of the nature of these assumptions and conditions may be found in the relevant notes to the financial statements.

Capitalised development costs

Included in intangible assets (Note 12) at the end of the year is an amount of \$86,000 (2014: \$97,000) relating to capitalised development cost. Development costs are only capitalised by the Group when it can be demonstrated that the technical feasibility of completing the intangible asset is valid so that the asset will be available for use or sale.

Taxation

The Group's accounting policy for taxation requires management's judgement as to the types of arrangements considered to be a tax on income in contrast to an operating cost. Judgement is also required in assessing whether deferred tax assets and certain deferred tax liabilities are recognised on the statement of financial position. Deferred tax assets, including those arising from unrecouped tax losses, capital losses and temporary differences, are recognised only where it is considered more likely than not that they will be recovered, which is dependent on the generation of sufficient future taxable profits.

Judgements are also required about the application of income tax legislation. These judgements and assumptions are subject to risk and uncertainty, hence there is a possibility that changes in circumstances will alter expectations, which may impact the amount of deferred tax assets and deferred tax liabilities recognised on the statement of financial position and the amount of other tax losses and temporary differences not yet recognised. In such circumstances, some or all of the carrying amounts of recognised deferred tax assets and liabilities may require adjustment, resulting in a corresponding credit or charge to the consolidated statement of comprehensive income.

Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact expenses and equity.

The Group measures the cost of share-based payments at fair value at the grant date using the Black-Scholes formula taking into account the terms and conditions upon which the instruments were granted.

Estimation of useful lives of assets

The estimation of the useful lives of assets has been based on historical experience as well as manufacturers' warranties (for plant and equipment), lease terms (for leased equipment) and turnover policies (for motor vehicles). In addition, the condition of the assets is assessed at least once per year and considered against the remaining useful life. Adjustments to useful lives are made when considered necessary.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

2 Segment Information

Management has determined the operating segments based on the reports reviewed by the Board that are used to make strategic decisions. As the Board monitors business activity by each country the Group operates in, management has determined the Geographic Segment report to be of primary interest to users of this financial report.

Geographical segments

The consolidated entity operates in the regions identified as Australia, Singapore, Malaysia and others.

The following tables present revenue and profit information and certain asset and liability information regarding geographical segments for the years ended 31 December 2015 and 31 December 2014.

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Total \$'000
Year ended 31 December 2015					
Revenue					
Sales to external customers	15,640	6,252	14,381	2,311	38,584
Total segment revenue	15,640	6,252	14,381	2,311	38,584
Segment results					
Earnings before interest and tax	3,142	2,060	1,905	(999)	6,108
Net interest	56	(2)	(141)	(6)	(93)
Share of loss of associates	-	-	-	(13)	(13)
Profit before income tax					6,002
Income tax benefit					(1,651)
Net profit for the year					4,351
Assets and liabilities					
Segment assets	10,583	2,658	16,593	1,617	31,451
Investment in associates					937
Total assets					32,388
Segment liabilities	3,381	631	5,298	202	9,512
Total liabilities					9,512
Other segment information					
Capital expenditure	(32)	(22)	(759)	(46)	(859)
Depreciation	(9)	(17)	(57)	(15)	(98)
Amortisation	-	-	(14)	(2)	(16)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

2 Segment Information (continued)

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Total \$'000
Year ended 31 December 2014					
Revenue					
Sales to external customers	13,745	5,651	13,772	3,412	36,580
Total segment revenue	13,745	5,651	13,772	3,412	36,580
Segment results					
Earnings before interest and tax	2,645	2,097	2,616	(473)	6,885
Net interest	50	(2)	-	(5)	43
Share of loss of associates	-	-	-	(3)	(3)
Profit before income tax					6,925
Income tax benefit					359
Net profit for the year					7,284
Assets and liabilities					
Segment assets	9,600	3,896	13,691	2,040	29,227
Investment in associates					1,044
Total assets					30,271
Segment liabilities	2,354	696	5,473	183	8,706
Total liabilities					8,706
Other segment information					
Capital expenditure	(4)	(17)	(6,748)	(9)	(6,778)
Depreciation	(10)	(15)	(59)	(20)	(104)
Amortisation	-	(1)	(12)	(1)	(14)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

2 Segment Information (continued)

Business segments

The Group operates in two industry segments.

Business Industry	Products/Services
Health	Sale of vitamins and supplements
Investment	General investments

The following table presents revenue, expenditures and certain asset and liabilities information regarding business segments for the years ended 31 December 2015 and 31 December 2014.

Year ended 31 December	2015			2014		
	Health \$'000	Investment \$'000	Total \$'000	Health \$'000	Investment \$'000	Total \$'000
Revenue						
Sales to external customers	38,584	-	38,584	36,580	-	36,580
Result						
Segment results	6,754	(21)	6,733	7,501	(16)	7,485
Unallocated expenses	-	-	(638)	-	-	(603)
Earnings before interest and tax			6,095			6,882
Net interest			(93)			43
Profit before income tax			6,002			6,925
Income tax benefit / (expense)			(1,651)			359
Net profit for the year			4,351			7,284
Assets and liabilities						
Segment assets	31,451	937	32,388	29,227	1,044	30,271
Total assets			32,388			30,271
Segment liabilities	9,505	7	9,512	8,698	8	8,706
Total liabilities			9,512			8,706
Other segment information						
Capital expenditure	(859)	-	(859)	(6,778)	-	(6,778)
Depreciation	(98)	-	(98)	(104)	-	(104)
Amortisation	(16)	-	(16)	(14)	-	(14)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

3 Revenue and Expenses

	2015 \$'000	2014 \$'000
(a) Other income		
Realised gain on foreign exchange	17	17
Other income	20	100
	37	171
(b) Administrative expenses		
Legal and other professional fees	(336)	(365)
Consultants	(806)	(701)
Allowance for impairment loss	13	(27)
Wages, salaries and other employee expenses	(10,563)	(9,982)
Defined contribution superannuation expense	(752)	(674)
Travelling expenses	(265)	(361)
Share based payment expense	(254)	(232)
Depreciation	(98)	(104)
Amortisation	(16)	(14)
Other administrative expenses	(429)	(190)
	(13,506)	(12,650)
(c) Other expenses		
Product registration costs	(250)	(209)
Loss on disposal of property, plant and equipment	(4)	(3)
	(254)	(212)
(d) Finance income		
Interest received - external parties	161	174
	161	174
(e) Finance expenses		
Interest expense - external parties	(165)	(60)
Bank charges	(89)	(71)
	(254)	(131)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

4 Earnings per share

(a) Earnings used in calculating earnings per share

	2015 \$'000	2014 \$'000
Net profit attributable to equity holders from continuing operations	4,351	7,284
(Profit) / loss attributable to non-controlling interest	40	(4)
Earnings used to calculate basic and dilutive earnings per share	4,391	7,280

(b) Weighted average number of shares

	2015 Number	2014 Number
Weighted average number of ordinary shares for basic earnings per share	55,641,822	56,067,408
Adjusted weighted average number of ordinary shares for diluted earnings per share. Long Term Incentive Plan shares are classified as dilutive for the purposes of this calculation.	57,063,906	56,712,408

5 Income Taxes

a) Income Tax Expense

	2015 \$'000	2014 \$'000
The major components of income tax expense are:		
<i>Income Statement:</i>		
<i>Current income tax</i>		
Current income tax charge	1,541	1,733
Tax benefits arising from previously unrecognised tax losses of prior years	-	(2,112)
Prior year under / (over) provision	44	52
<i>Deferred income tax</i>		
Write back of deferred tax assets	100	-
Relating to origination and reversal of temporary differences	(34)	(32)
Income tax (benefit) / expense reported in the income statement	1,651	(359)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

5 Income Taxes (continued)

(b) A reconciliation between tax expense and the product of accounting profit before income tax multiplied by the Group's applicable income tax rate is as follows:

	2015 \$'000	2014 \$'000
Total accounting profit before income tax	6,002	6,925
At the parent entity's statutory income tax rate of 30% (2014: 30%)	1,801	2,078
Adjustment in respect of current income tax of previous year	44	52
Write back of deferred tax assets	100	-
Foreign tax rate adjustment	(127)	(311)
Travel and staff amenities expenses	22	3
Share based payments	80	69
Other income/(expenditure) not allowable for income tax purposes	(210)	(81)
Deferred tax asset recognised during financial year	(46)	(2,112)
Tax losses and timing differences not brought to account / (recognised)	(13)	(57)
Aggregate income taxes	1,651	(359)
The applicable weighted tax rates are as follows:	28%	(5%)

(c) Deferred income taxes at 31 December relates to the following:

<i>Deferred tax assets/ (liabilities)</i>		
Deferred tax assets relating to Australian Tax Group losses carried forward	-	1,250
Doubtful debts	3	10
Inventory obsolescence	21	17
Property, plant and equipment	-	(4)
Trade and other receivables	-	(4)
Provision for annual leave	55	35
Provision for long service leave	17	21
Other provision	90	77
Net deferred tax assets/ (liabilities)	186	1,402
<i>Presented in the consolidated Statement of Financial Position as follows:</i>		
Deferred tax assets	207	1,411
Deferred tax liabilities	(21)	(9)
	186	1,402

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

5 Income Taxes (continued)

(d) Tax losses

The Group has carry forward tax losses of SGD\$18.9 million (A\$18.3m) held within a wholly owned subsidiary, for which no deferred tax asset is brought to account. These losses are available indefinitely for offset against taxable income of the companies in which those losses arose. The benefit of these tax losses has not been brought to account as the probable recognition criteria has not been satisfied. Were these tax losses to be recognised, it would result in a deferred tax asset at the Singaporean company tax rate of 17%.

The Group had \$4.2m of recognised tax losses as at 31 December 2014, relating solely to the Australian consolidated tax group. These were recouped during the 2015 financial year.

(e) Tax consolidation

(i) Members of the tax consolidated group and the tax sharing agreement

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was for the tax period ended 30 June 2003. Members of the group have entered into a tax sharing agreement that provides for the allocation of income tax liabilities between the entities should the head entity default on its tax payment obligations. No amounts have been recognised in the financial statements in respect of this agreement on the basis that the possibility of default is remote.

(ii) Tax effect accounting by members of the tax consolidated group

Measurement method adopted

The head entity and the controlled entities in the tax consolidated group continue to account for their own current and deferred tax amounts. Current and deferred tax amounts are measured in a systematic manner that is consistent with the broad principles in AASB 112 *Income Taxes*.

The current and deferred tax amounts of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "Stand-Alone Taxpayer" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts receivable from (payable to) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised. Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

Nature of the tax funding agreement

Members of the tax consolidated group have entered into a tax funding agreement, which sets out the funding obligations of members of the tax consolidated group. Payments required to / (from) head entity are equal to the current tax liability / (assets) assumed from the members of the tax consolidated group. The inter-entity receivable (payable) is at call.

Tax consolidation contributions / (distributions)

The Company has recognised the following amount as tax-consolidation contribution adjustment:

	2015 \$'000	2014 \$'000
Total increase in intercompany receivable of Vita Life Sciences Limited	1,244	909

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

6 Cash and cash equivalents

	2015 \$'000	2014 \$'000
Cash at bank and in hand (a)	8,097	7,211
Short term deposit (b)	1,637	1,947
Total cash and cash equivalents	9,734	9,158

(a) Cash at bank of \$8,097,000 (2014: \$7,211,000) earns interest at floating rates based on daily bank deposit rates.

(b) Short term deposit earns interest at the respective short-term deposit rates.

(c) The fair value of cash equivalents for the Group is \$9,734,000 (2014: \$9,158,000).

	2015 \$'000	2014 \$'000
Net profit after tax	4,351	7,284
Adjustments for non-cash income and expense items:		
Depreciation	98	104
Amortisation	16	14
Net (gain) loss on disposal of property, plant & equipment	(20)	3
Shared based payment expense	254	232
Allowance for / (reversal of) impairment loss	(13)	27
	4,686	7,664
Increase/decrease in assets and liabilities:		
Decrease / (increase) in inventories	(1,581)	1,098
Decrease in investment in associates	13	3
(Increase) in receivables	(408)	(1,191)
(Increase) in other assets	(117)	(56)
(Increase) decrease in deferred tax balances	1,204	(1,284)
(Decrease)/ increase in current income tax payable	(261)	(94)
(Decrease) in trade and other payables	1,473	(93)
(Decrease) / increase in other liabilities	126	(201)
Effect of foreign exchange translation of assets and liabilities	(212)	269
Net cash provided by operating activities	4,923	6,115

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

7 Trade and other receivables

	2015 \$'000	2014 \$'000
Current		
Trade receivables, third parties	4,844	4,752
Allowance for impairment loss (a)	(21)	(34)
	4,823	4,718
Other receivables:		
Other receivables (b)	1,641	1,306
Net tax receivable	18	17
	6,482	6,041

(a) Allowance for impairment loss

Trade receivables are non-interest bearing and generally on 30 to 90 day terms. A provision for impairment loss is recognised when there is objective evidence that an individual trade receivable is impaired. An impairment benefit of \$13,000 (2014: impairment expense of \$27,000) has been recognised by the Group. These amounts have been included in the administrative expenses.

Movements in the provision for impairment loss were as follows:

	2015 \$'000	2014 \$'000
At 1 January 2015	34	7
Charge for the year	(13)	27
At 31 December 2015	21	34

(b) Other receivables are non-interest bearing and have repayment terms between 30 to 90 days. Other balances within trade and other receivables do not contain impaired assets and are not past due. It is expected that these other balances will be received when due.

(c) Fair value

The carrying value for trade and other receivables is assumed to approximate their fair value. The maximum exposure to credit risk is the fair value of receivables.

8 Inventories

	2015 \$'000	2014 \$'000
Current		
Raw materials at cost	1,620	950
Finished goods at lower of cost and net realisable value	4,973	4,062
	6,593	5,012

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

9 Other assets

	2015 \$'000	2014 \$'000
Current		
Prepayments	406	410
Security deposits	309	188
	715	598
Non- Current		
Prepayments	5	-
	720	1,196

10 Investment in Associates

	2015 \$'000	2014 \$'000
Non- current		
<i>Unlisted</i>		
- Mitre Focus Sdn Bhd (a)	937	1,044
Investment in associate	937	1,044

(a) Details of the carrying value of investment and share of profit in associate:

	2015 \$'000	2014 \$'000
Mitre Focus Sdn Bhd		
- Investment in associate at cost	-	-
- Loan to associate	904	998
- Cumulative share of associate's profit	33	46
Carrying value of investment in associate	937	1,044

	Measurement	Place of	Ownership Interest	
			31 December %	31 December %
(b) Investment details				
Name of Company				
<i>Unlisted</i>				
- Mitre Focus Sdn Bhd	Equity Method	Malaysia	6.3	6.3

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

10 Investment in Associates (continued)

(c) Summarised financial information

The following illustrates summarised financial information relating to the Group's associate:

Extract from the associate's statement of financial position:

	2015 \$'000	2014 \$'000
Current assets	4,852	4,787
Non - current assets	1,971	2,380
	6,823	7,167
Current liabilities	(4,379)	(4,248)
Non - current liabilities	(160)	(175)
	(4,539)	(4,423)
Net assets	2,284	2,744
Share of associate's net assets	144	173

Extract from the associate's income statement:

Revenue	2,869	3,173
Net loss	(209)	(51)
Other comprehensive income	-	-
Total comprehensive loss	(209)	(51)

- (d) The reporting date of the associate is 31 December 2015. The reporting date coincides with the Company's reporting date.
- (e) The loan to associate is interest free and has no fixed repayment term.
- (f) As at 31 December 2015, there are no contingent liabilities relating to the associate.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

11 Property, plant and equipment

	Property and Buildings \$'000	Leasehold improvements \$'000	Plant and equipment \$'000	Leased Plant and Equipment \$'000	Total \$'000
Year ended 31 December 2015					
At 1 January 2015 net of accumulated depreciation and impairment	6,705	34	171	-	6,910
Additions	611	7	233	28	879
Disposals	-	(10)	(10)	-	(20)
Exchange differences	-	(2)	(37)	(3)	(42)
Depreciation / amortisation for the year	-	(16)	(76)	(6)	(98)
At 31 December 2015 net of accumulated depreciation and impairment	7,316	13	281	19	7,629
At 31 December 2015					
Cost value	7,316	419	2,121	147	10,003
Accumulated depreciation and impairment	-	(406)	(1,855)	(113)	(2,374)
Impairment	-	-	-	-	-
Net carrying amount	7,316	13	266	34	7,629

	Property and Buildings \$'000	Leasehold improvements \$'000	Plant and equipment \$'000	Leased Plant and Equipment \$'000	Total \$'000
Year ended 31 December 2014					
At 1 January 2014 net of accumulated depreciation and impairment	-	70	216	-	286
Additions	6,705	-	47	-	6,752
Disposals	-	(8)	(6)	-	(14)
Exchange differences	-	(2)	(8)	-	(10)
Transfer to Assets Held for Sale ^	-	-	-	-	-
Depreciation / amortisation for the year	-	(26)	(78)	-	(104)
At 31 December 2014 net of accumulated depreciation and impairment	6,705	34	171	-	6,910
At 31 December 2014					
Cost value	6,705	351	1,772	119	8,947
Accumulated depreciation and impairment	-	(317)	(1,601)	(119)	(2,037)
Net carrying amount	6,705	34	171	-	6,910

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

12 Intangible assets

	Product Development costs \$'000	Total \$'000
Year ended 31 December 2015		
At 1 January 2015 net of accumulated depreciation and impairment	97	97
Additions	28	28
Impairment / amortisation	(16)	(16)
Exchange differences	(23)	(23)
At 31 December 2015 net of accumulated depreciation and impairment	86	86
At 31 December 2015		
Gross carrying amount	431	431
Accumulated amortisation and impairment	(345)	(345)
Total	86	86

	Product Development costs \$'000	Total \$'000
Year ended 31 December 2014		
At 1 January 2015 net of accumulated depreciation and impairment	83	83
Additions	26	26
Impairment / amortisation	(14)	(14)
Exchange differences	2	2
At 31 December 2014 net of accumulated depreciation and impairment	97	97
At 31 December 2014		
Gross carrying amount	426	426
Accumulated amortisation and impairment	(329)	(329)
Total	97	97

Development costs

Development costs are carried at cost less accumulated amortisation and accumulated impairment losses. This intangible asset has been assessed as having a finite life and is amortised using the straight line method over a period of 3 years. The amortisation has been recognised in the statement of comprehensive income in the line item 'administrative expense'. If an impairment indication arises, the recoverable amount is estimated and an impairment loss is recognised to the extent that the recoverable amount is lower than the carrying amount.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

13 Trade and other payables

	2015 \$'000	2014 \$'000
Current		
Trade payables (a)	2,849	1,929
Net tax payable	280	225
Other payables and accruals	2,656	2,158
	5,785	4,312

- a) Trade payables are non-interest bearing and are normally settled within 90-day terms. Other payables are non-interest bearing and have an average term of 3 months.

14 Interest bearing loans and borrowings

	2015 \$'000	2014 \$'000
Current		
Property facility - secured (a)	243	260
	243	260
Non - Current		
Property facility - secured (a)	2,567	3,094
	2,567	3,094

At the balance date, the following financing facilities had been negotiated and were available:

	2015 \$'000	2014 \$'000
Total facilities available:		
Property facility (a)	3,071	3,375
Bank overdraft (b)	200	200
	3,271	3,575
Facilities utilised at balance date:		
Property facility (a)	2,810	3,354
	2,810	3,354
Facilities not utilised at balance date:		
Property facility (a)	261	21
Bank overdraft (b)	200	200
	461	221

b) Property finance facility

Trade property facility is provided by a Malaysian bank to the Group's main operating subsidiary in Malaysia. The interest rate for the facility as at 31 December 2015 is fixed at 4.25% (2014: 5.22%) for a further term of 108 months from 1 January 2015. The facility is secured by a charge over the premises.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

14 Interest bearing loans and borrowings (continued)

(a) Bank overdrafts

Interest on bank overdrafts is charged at prevailing market rates. The weighted average interest rate for all overdrafts as at 31 December 2015 is 9.63% p.a. (2014: 10.11% p.a.) The bank overdraft of the controlled entity is secured by way of a pledge of the short term deposits of the controlled entity.

(b) Default and breaches

During the current and prior year, there were no defaults or breaches on any of the loans.

15 Provisions

	Employee Entitlements \$'000	Total \$'000
Consolidated		
Balance at 1 January 2015	592	592
Charged during year	1,165	1,165
Used during year	(866)	(866)
Foreign exchange difference	(173)	(173)
	718	718
Balance at 31 December 2015		
At 31 December 2015		
Current	663	663
Non-Current	55	55
	718	718
At 31 December 2014		
Current	523	523
Non-Current	69	69
	592	592

(a) Employee entitlements

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

16 Contributed equity

	2015 Number	2014 Number	2015 \$	2014 \$
Issued and paid up capital				
Ordinary shares	57,197,839	56,466,189	44,911,156	45,428,667
Ordinary shares				
Balance at beginning of the year	56,466,189	56,250,650	45,428,667	46,100,480
Share buy back (a)	(625,850)	(429,461)	(605,511)	(671,813)
Cancellation of Plan Shares of certain:				
- Employees and Directors	(242,500)	-	-	-
Issue of shares to employee / director (b)	1,600,000	645,000	-	-
Plan shares exercised	-	-	88,000	-
Balance at end of the year	57,197,839	56,466,189	44,911,156	45,428,667

(a) Share Buy-Back

On 25 May 2015, the Company announced an on-market share buy-back of up to 15% of the Company's shares on issue funded from the Group's existing cash reserves. During the financial year ended 31 December 2015, the Company bought back 625,850 shares for total consideration of \$599,517, excluding costs of \$5,994.

(b) Issue of Long Term Incentive Plan Shares to key executives

During the year ended 31 December 2015, the Company approved loans to three senior executives of the Group totalling \$2,504,000 in order for these executives to purchase a total of 1,600,000 shares under the Company's Long Term Incentive Plan. The issue of these shares was ratified at the Company's Annual General Meeting held on 25 May 2015.

The cost of the equity-settled transactions is measured by reference to the fair value of the equity instruments at the date at which they were granted. The cost is recognised in the income statement together with a corresponding increase in equity, over the period in which the performance and / or service conditions are fulfilled (the vesting period), ending on the date on which the employees become fully entitled to the award (the vesting date).

For the full year ended 31 December 2015, the Company recognised \$254,000 (2014: \$232,000) in the income statement with a corresponding increase in employee share based payment reserve.

(c) Capital management

When managing capital, management's objective is to ensure the Company continues as a going concern as well as to maintain optimal returns for shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.

Management constantly assesses the capital structure to take advantage of favourable costs of capital and / or high returns on assets. As the market is continuously changing, management may issue dividends to shareholders, return capital to shareholders, issue new shares, increase the short or long term borrowings or sell assets to reduce borrowings.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

16 Contributed equity (continued)

(d) Dividends

The Directors declared an unfranked interim dividend of 1.5 cents per share and an unfranked final dividend of 2.25 cents per share in respect of the financial year ended 31 December 2015 (2014: interim dividend of 1.5 cent unfranked and an unfranked final dividend of 2.0 cents).

The final dividend of 2.25 cents per share has not been recognised in these consolidated financial statements as it was declared subsequent to 31 December 2015.

	2015 Cents per Share	2014 Cents per Share	2015 \$'000	2014 \$'000
Fully paid ordinary shares				
Final dividend for the previous financial year				
- No franking credits attached	2.00	2.00	1,116	1,124
Interim dividend for the financial year				
- No franking credits attached	1.50	1.50	831	840
	3.50	3.50	1,947	1,964

The Group has no remaining imputation credits to distribute at 31 December 2015.

17 Net tangible assets per share

	2015 \$	2014 \$
Net assets per share	0.40	0.38
Net tangible assets per share	0.40	0.36
	Number	Number
Number of ordinary shares for net assets per share	57,197,839	56,466,189

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

18 Subsidiaries

Name	Place of Incorporation	Percentage of Equity Interest	
		2015 %	2014 %
Tetley Research Pty Limited	Australia	100	100
Tetley Treadmills Pty Limited	Australia	100	100
Tetley Manufacturing Pty Limited	Australia	100	100
Vimed Bio Sciences Pty Limited	Australia	100	100
Allrad No 19 Pty Limited	Australia	100	100
Lovin Pharma International Limited	Ireland	100	100
Herbs of Gold Pty Limited	Australia	100	100
Herbs of Gold (Shanghai) Co. Limited	People's Republic of China	100	100
VitaHealth Laboratories Australia Pty Limited	Australia	100	100
Vita Institute of Health Pty Ltd (formerly Premier Foods Australia Pt	Australia	100	100
VitaHealth Australia Pty Ltd	Australia	100	-
Vita Corporation Pte Limited	Singapore	100	100
Herbs of Gold (S) Pte Ltd (formerly Supplements World Pte Ltd)	Singapore	100	100
VitaHealth Laboratories (HK) Limited	Hong Kong	100	100
Vita Healthcare Asia Pacific Sdn Bhd	Malaysia	100	100
Swiss Bio Pharma Sdn Bhd	Malaysia	100	100
VitaHealth Biotech Sdn Bhd (formerly Vita ron Japya Sdn Bhd)	Malaysia	100	100
Vita Lifesciences Sdn Bhd (formerly known as Vitaherbs (M) Sdn	Malaysia	100	100
Vita Science Sdn Bhd	Malaysia	100	100
Herbs of Gold Sdn Bhd	Malaysia	100	100
VitaHealth Asia Pacific (S) Pte Limited	Singapore	100	100
Vita Life Sciences (S) Pte Limited	Singapore	100	100
VitaHealth IP Pte Limited	Singapore	100	100
Vita Life Sciences (Thailand) Co. Ltd	Thailand	49	49
Vitahealth (Thailand) Co. Ltd	Thailand	74	74
Vita Health Vietnam Company Limited	Vietnam	100	100
Sino Metro Developments Limited	British Virgin Island	100	100
VitaHealth (Macao Commercial Offshore) Limited	Hong Kong	100	100
Pharma Direct Sdn Bhd	Malaysia	100	100
PT. Vita Health Indonesia	Indonesia	100	100

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2015

19 Subsequent events

Final Dividend

On 18 February 2016, the Directors declared a final unfranked dividend of 2.25 cents per share in respect of the financial year ended 31 December 2015.

Subsequent to the year end, other than that referred to in the financial statements and notes thereto, there are no subsequent events after balance date that affect the operating results or financial position of the Company and its subsidiaries.

20 Information on audit or review

This preliminary final report is based on accounts to which one of the following applies

- | | |
|---|-------------------------------------|
| The accounts have been audited | <input type="checkbox"/> |
| The accounts have been subject to review | <input type="checkbox"/> |
| The accounts are in the process of being audited or subject to review | <input checked="" type="checkbox"/> |
| The accounts have not yet been audited or reviewed | <input type="checkbox"/> |

Description of likely dispute or qualification if the accounts have not yet been audited or subject to review or are in the process of being audited or subjected to review.

Not applicable

Compliance Statement

1. This report has been prepared in accordance with ASX Listing Rule 4.3A, Australian Accounting Standards (including Australian Accounting Interpretations) and other standards acceptable to the ASX.
2. This report, and the financial statements upon which the report is based, use the same accounting policies.
3. This report does give a true and fair view of the matters disclosed.
4. This report is based on financial statements which are in the process of being audited, and the audit report is not expected to contain any qualifications.
5. The entity has a formally constituted Audit Committee.

Monica Jovanov
Company Secretary
18 February 2016

VLS